Founded in 1876, Eli Lilly and Company is a global pharmaceutical leader engaged in the discovery, development, and commercialization of human prescription medicines. The company maintains a broad therapeutic focus spanning cardiometabolic health, oncology, neuroscience, and immunology. Currently, Lilly is heavily focused on scaling its cardiometabolic business driven by blockbuster incretin therapies like Mounjaro and Zepbound, advancing pipeline candidates in Alzheimer's disease and next-generation obesity treatments, and making major capital investments to expand its global manufacturing capacity.
Executive summary
Eli Lilly has established global leadership in the metabolic therapeutics market, generating $65.19 billion in revenue during fiscal 2025 on 45.0% year-over-year growth driven by tirzepatide1,8. The company's competitive position is fortified by formulation patents extending through 2036 in the United States and a cumulative $50 billion manufacturing capital buildout8,11. While the stock trades at 32.25 times forward earnings and faces U.S. drug pricing headwinds, robust volume growth and next-generation pipeline assets like retatrutide provide durable long-term cash flow visibility8,14,30.
Sources cited here, 5 of 32
- 1stockrow.com
- 8sec.gov
- 11prnewswire.com
- 14biospace.com
- 30whitehouse.gov
Key figures
- Market cap
- $1.1T
- P/E, trailing
- 38.8
- P/E, next 12 months
- 32.3
- Revenue growth, last fiscal year
- 45.0%
- Net margin, last fiscal year
- 31.7%
The full analysis adds sections on competition, financials and valuation, recent news, upcoming catalysts, institutional investors and fund letters. See the plans or join the waitlist.